Gastric/Esophageal Trials

PCYC-1128-CA

PCYC-1128-CA – A phase1b/2 study of ibrutinib combination therapy in selected advanced gastrointestinal and genitourinary tumors – bladder, colon, gastric, renal

1. What type of cancer? What stage?
   1. Advanced GI cancer – gastric and colon
2. Who is eligible?
   1. Patients who have received prior chemotherapy
3. How will I be treated?
   1. Patients will receive ibrutinib with other chemotherapy or biologic therapy

S0820

S0820 – Phase III a double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-3 colon cancer

1. What type of cancer? What stage?
   1. Colorectal cancers or high-rick adenomas - polyps.
2. Who is eligible?
   1. Patients with stage 0, 1, 2, or 3 disease that is removed who desire prevention
3. How will I be treated?
   1. This study looks at using two drugs for prevention – Sulindac, non-steriodal anti-inflammatory, and eflornithine is a drug that has been shown in a preclinical data to have a role in cancer prevention.

CX-839-008

CX-839-008 – A phase III, randomized, placebo controlled study of Atezolizumab (Anti-PD-L1 Antibody) as monotherapy and in combination with platinum chemotherapy with untreated locally advanced or metastatic urothelial carcinoma

1. What type of cancer? What stage?
   1. Renal cell cancer
2. Who is eligible?
   1. Patients with disease progression after first-line therapy
3. How will I be treated?
   1. Adds CB-839 - a drug that inhibits tumor cell nutrient uptake - to treated with Cabozantinib - a small molecule tyrosine kinase inhibitor.

For physicians: more information about this specific trial at clinicaltrials.gov.